Cells to Surgery Quiz: April 2020
TLDR Certain surgical methods are better than routine incision for hidradenitis suppurativa, topical clindamycin and acitretin are effective treatments, men with HS have a risk of skin cancer, HS patients are more likely to die from heart problems, and specific genetic markers are linked to treatment response.
The "Cells to Surgery Quiz: April 2020" document from the Journal of Investigative Dermatology focused on diagnosing and managing hidradenitis suppurativa (HS), a chronic inflammatory skin disorder. It emphasized that routine incision and drainage (I&D) was ineffective for HS due to high recurrence rates, recommending punch debridement or unroofing instead. Topical clindamycin was noted as a first-line treatment for mild HS, while acitretin was preferred for more severe cases. A population-based cohort study involving 5,964 HS patients and 29,404 controls revealed significantly increased risks of cardiovascular-associated death and other major adverse cardiovascular events in HS patients. Additionally, a genetic study identified SNPs associated with adalimumab response, highlighting the need for personalized treatment approaches.
